Compare Lupin Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs CIPLA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN CIPLA LUPIN/
CIPLA
 
P/E (TTM) x 47.5 23.3 203.6% View Chart
P/BV x 2.4 2.4 102.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 LUPIN   CIPLA
EQUITY SHARE DATA
    LUPIN
Mar-19
CIPLA
Mar-19
LUPIN/
CIPLA
5-Yr Chart
Click to enlarge
High Rs986678 145.4%   
Low Rs720484 148.9%   
Sales per share (Unadj.) Rs369.5198.2 186.4%  
Earnings per share (Unadj.) Rs13.418.5 72.4%  
Cash flow per share (Unadj.) Rs37.435.0 106.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs303.7186.3 163.0%  
Shares outstanding (eoy) m452.49805.70 56.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.32.9 78.8%   
Avg P/E ratio x63.631.4 203.0%  
P/CF ratio (eoy) x22.816.6 137.5%  
Price / Book Value ratio x2.83.1 90.1%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m386,064468,031 82.5%   
No. of employees `00017.722.6 78.1%   
Total wages/salary Rs m31,51328,565 110.3%   
Avg. sales/employee Rs Th9,453.87,053.1 134.0%   
Avg. wages/employee Rs Th1,782.01,261.5 141.3%   
Avg. net profit/employee Rs Th343.0659.1 52.0%   
INCOME DATA
Net Sales Rs m167,182159,710 104.7%  
Other income Rs m3,6404,766 76.4%   
Total revenues Rs m170,822164,475 103.9%   
Gross profit Rs m28,82230,973 93.1%  
Depreciation Rs m10,85013,263 81.8%   
Interest Rs m3,0781,684 182.8%   
Profit before tax Rs m18,53420,791 89.1%   
Minority Interest Rs m-89-172 52.0%   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0175,695 158.3%   
Profit after tax Rs m6,06614,924 40.6%  
Gross profit margin %17.219.4 88.9%  
Effective tax rate %48.727.4 177.6%   
Net profit margin %3.69.3 38.8%  
BALANCE SHEET DATA
Current assets Rs m138,536124,266 111.5%   
Current liabilities Rs m61,29937,715 162.5%   
Net working cap to sales %46.254.2 85.3%  
Current ratio x2.33.3 68.6%  
Inventory Days Days8491 92.4%  
Debtors Days Days11295 118.5%  
Net fixed assets Rs m127,516105,190 121.2%   
Share capital Rs m9051,611 56.2%   
"Free" reserves Rs m136,517148,511 91.9%   
Net worth Rs m137,422150,123 91.5%   
Long term debt Rs m66,41738,301 173.4%   
Total assets Rs m279,494239,633 116.6%  
Interest coverage x7.013.3 52.6%   
Debt to equity ratio x0.50.3 189.4%  
Sales to assets ratio x0.60.7 89.7%   
Return on assets %3.36.9 47.2%  
Return on equity %4.49.9 44.4%  
Return on capital %8.911.8 75.3%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41457,410 103.5%   
Fx outflow Rs m22,28219,041 117.0%   
Net fx Rs m37,13238,368 96.8%   
CASH FLOW
From Operations Rs m16,66016,911 98.5%  
From Investments Rs m-32,825-16,687 196.7%  
From Financial Activity Rs m7,441-3,487 -213.4%  
Net Cashflow Rs m-8,724-3,451 252.8%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Oct 18, 2019 (Close)

TRACK LUPIN

LUPIN - WOCKHARDT COMPARISON

COMPARE LUPIN WITH

MARKET STATS